Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Moderna (MRNA) Inks Vaccine Manufacturing Deal With Resilience

By Zacks Investment ResearchStock MarketsSep 08, 2021 10:29PM ET
www.investing.com/analysis/moderna-mrna-inks-vaccine-manufacturing-deal-with-resilience-200601439
Moderna (MRNA) Inks Vaccine Manufacturing Deal With Resilience
By Zacks Investment Research   |  Sep 08, 2021 10:29PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Moderna (NASDAQ:MRNA), Inc. MRNA and the newly founded manufacturing and technology company, National Resilience, Inc. (Resilience), signed a multi-year agreement for manufacturing of the drug substance for Moderna’s COVID-19 vaccine.

Per the terms of the agreement, Resilience will produce messenger RNA (mRNA) for Moderna’s COVID-19 vaccine at its facility in Mississauga, Ontario in Canada. The vaccine will then be distributed worldwide.

Currently, Moderna is seeking “full” approval for its COVID-19 vaccine, mRNA-1273, in the United States. A potential approval in the United States may lead to approval in other countries amid the pandemic. The agreement with Resilience will help the company to support the growing demand for its vaccine globally.

Please note that Resilience was founded last year and is focused on building a sustainable network of high-tech, end-to-end manufacturing solutions that can support manufacturing of the drugs quickly, safely, and at scale.

Moderna also has similar agreements in place with other companies including Sanofi (NASDAQ:SNY) SNY, Catalent (NYSE:CTLT) CTLT, Thermo Fisher Scientific TMO, and Rovi to support the manufacturing and packaging of its COVID-19 vaccine.

Moderna is also planning to construct a state-of-the-art mRNA vaccine manufacturing facility in Canada and signed a Memorandum of Understanding with Canada’s government last month for the same. The company has also started the expansion of the Moderna Technology Center in Norwood, MA to transform it from a production and lab space to an industrial technology center.

These developments on the manufacturing front will likely help Moderna to support the development of its mRNA-based vaccines and therapies targeting various indications for clinical as well as commercial purposes. The company plans to deliver an aggregate of 800 million to 1 billion doses of mRNA-1273 in 2021. It expects to increase its global capacity for the COVID-19 vaccine to up to 2 billion doses in 2022 in case of production of 100 microgram doses or up to 3 billion doses in case of production of only the booster dose of the vaccine at 50 microgram level.

Shares of Moderna have skyrocketed 304.5% so far this year compared with the industry’s rise of 2.3%.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

Moderna’s COVID-19 vaccine is authorized for emergency/conditional/temporary use in several countries including the United States and Europe. While in the United States it is available for adults only, the vaccine can be administered to adolescents as well in Europe. The company is seeking authorization for use of its vaccine in adolescents in the United States as well as a “full” approval in adults. A third or booster dose of the vaccine is already authorized for immunocompromised individuals in the United States and may get authorization for all adults soon in the country and in Europe.

The company’s vaccine generated sales of nearly $6 billion in the first half of 2021. The company expects total COVID-19 vaccine revenues to be approximately $19.2 billion for full-year 2021.

The agreements to manufacture the drug substance, fill-finish of vials, and others help Moderna to focus on innovation of its pipeline, especially COVID-19 vaccine booster doses, which are still being modified for coronavirus variants.

Zacks Rank

Moderna currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.


Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Sanofi (SNY): Free Stock Analysis Report

Thermo Fisher Scientific Inc. (NYSE:TMO): Free Stock Analysis Report

Moderna, Inc. (MRNA): Free Stock Analysis Report

Catalent, Inc. (CTLT): Free Stock Analysis Report

To read this article on Zacks.com click here.
Moderna (MRNA) Inks Vaccine Manufacturing Deal With Resilience
 

Related Articles

Moderna (MRNA) Inks Vaccine Manufacturing Deal With Resilience

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email